Evidence map›Paper›PMID 42614751›Full record

ArticleAnnals of clinical epidemiology2026

Effect of the revision of the recommended vaccination schedule for preventing vertical transmission of hepatitis B virus on vaccination status of infants in Japan.

Hayato Yamana, Sachiko Ono, Nobuaki Michihata, Kohei Uemura, Hideo Yasunaga

Abstract read
In one paragraph

Article in Annals of clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hayato YamanaData Science Center, Jichi Medical University, Shimotsuke, Japan.
Sachiko OnoDepartment of Eat-loss Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo, Japan.
Nobuaki MichihataCancer Prevention Center, Chiba Cancer Center Research Institute, Chiba, Japan.
Kohei UemuraDepartment of Biostatistics & Bioinformatics, Interfaculty Initiative in Information Studies, The University of Tokyo, Bunkyo, Japan.
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Bunkyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 1986, a strategy of vaccinating infants at 2, 3, and 5 months of age was implemented in Japan to prevent the vertical transmission of the hepatitis B virus. This strategy was revised in 2013 to vaccinate infants at birth, 1 month, and 6 months of age. We aimed to evaluate the effect of this policy change on the vaccination status of infants born to mothers with positive hepatitis B surface antigen.

methodsWe identified infants born between April 2009 and March 2021 from the JMDC Claims Database. Administration of hepatitis B immunoglobulin at birth was used to identify infants who received preventive measures against vertical transmission. The timing of hepatitis B vaccine administration within 12 months of birth was compared between old (born between April 2009 and September 2013) and new (born between October 2013 and March 2021) groups.

resultsAmong the 77,797 and 510,584 infants born before and after October 1 2013, respectively, 190 (0.24%) and 732 (0.14%) were analyzed. The proportion of infants receiving at least one dose of the vaccine increased from 63% to 96% (

conclusionsThe change in strategy against the vertical transmission of hepatitis B virus resulted in an increased rate of receiving the first dose of the vaccine and a decreased rate of timely completion of the recommended doses.

Indexed as

databasehealth insurance claimsHepatitis Bobservational studyvaccines

Identifiers

PMID42614751
PMCPMC13482557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.